{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T10:05:16Z","timestamp":1648721116709},"reference-count":16,"publisher":"PAGEPress Publications","issue":"4","license":[{"start":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T00:00:00Z","timestamp":1640131200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Ital Urol Androl"],"abstract":"<jats:p>To the Editor, Benign Prostatic Hyperplasia (BPH) is one of the main causes of patients seeking urological counselling in Western countries. It has been estimated that nearly 70 percent of United States men between the ages of 60 and 69 years, and nearly 80 percent of men \u2265 70 years, have some degree of BPH [...].<\/jats:p>","DOI":"10.4081\/aiua.2021.4.501","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T07:57:58Z","timestamp":1640159878000},"page":"501-504","source":"Crossref","is-referenced-by-count":0,"title":["Preliminary results of a randomized crossover clinical trial comparing a new electromagnetic and vibrating device and alpha-blocker agents in patients affected by bladder outlet obstruction secondary to benign prostatic hyperplasia"],"prefix":"10.4081","volume":"93","author":[{"given":"Simone","family":"Brardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Cevenini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2021,12,22]]},"reference":[{"key":"46872","unstructured":"McVary KT. Epidemiology and pathophysiology of benign prostatic hyperplasia. In: UpToDate, post TW (Ed), UpToDate, Waltham, MA. 2020."},{"key":"46873","unstructured":"McVary KT. Lower urinary tract symptoms in men. In: UpToDate, post TW (Ed), UpToDate, Waltham, MA. 2020."},{"key":"46874","doi-asserted-by":"crossref","unstructured":"Fourcade RO, Lacoin F, Roupr\u00eat M, et al. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J Urol. 2012; 30:419-426.","DOI":"10.1007\/s00345-011-0756-2"},{"key":"46875","doi-asserted-by":"crossref","unstructured":"Gratzke C, Bachmann A, Descazeaud A, et al. EAU Guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015; 67:1099-1109.","DOI":"10.1016\/j.eururo.2014.12.038"},{"key":"46876","doi-asserted-by":"crossref","unstructured":"Roehrborn CG, Siami P, Barkin J, et al. For the CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008; 179:616-621.","DOI":"10.1016\/j.juro.2007.09.084"},{"key":"46877","doi-asserted-by":"crossref","unstructured":"BinhiV, Savin A. Effects of weak magnetic fields on biological systems: physical aspects, Phys Us pekhi. 2003; 46:259-291.","DOI":"10.1070\/PU2003v046n03ABEH001283"},{"key":"46878","doi-asserted-by":"crossref","unstructured":"McFarlane JP, Foley SJ, de Winter P, et al. Acute suppression of idiopathic detrusor instability with magnetic stimulation of the sacral nerve roots. Br J Urol. 1997; 80:734-741.","DOI":"10.1046\/j.1464-410X.1997.00446.x"},{"key":"46879","doi-asserted-by":"crossref","unstructured":"Haddad JB, Obolensky AG, Shinnick P. The biologic effects and the therapeutic mechanism of action of electric and electromagnetic field stimulation on bone and cartilage: New findings and a review of earlier work. J Altern Complement Med. 2007; 13:485-490.","DOI":"10.1089\/acm.2007.5270"},{"key":"46880","unstructured":"Bosco C, Cardinale M. Nuove frontiere dell\u2019allenamento sportivo: le vibrazioni. Effetti sul comportamento meccanico del muscolo scheletrico. Coaching and Sport Science Journal. 1998; 3:53-59."},{"key":"46881","doi-asserted-by":"crossref","unstructured":"Flieger J, Karachalios T, Khaldi L, et al. Mechanical stimulation in the form of vibration prevents postmenopausal bone loss in ovariectomized rats. Calcif Tissue Int. 1998; 63:510-514.","DOI":"10.1007\/s002239900566"},{"key":"46882","doi-asserted-by":"crossref","unstructured":"Rodrigues MP, Paiva LL, Ramos JGL, Ferla L. Vibratory perineal stimulationfor the treatment of female stress urinary incontinence: A systematic review. Int Urogynecol J. 2018; 4:555-562.","DOI":"10.1007\/s00192-017-3444-y"},{"key":"46883","unstructured":"Brardi S, Biandolino P, Giovannelli V, et al. Possible applications of electromagnetic fields in the treatment of symptoms related to benign prostatic hyperplasia. Am J Urol Res. 2020; 5:006-010."},{"key":"46884","doi-asserted-by":"crossref","unstructured":"ElgoharyHM, Tantawy SA. Pulsed electromagnetic field with or without exercise theraphy in the treatment of benign prostatic hyperplasia. J Phys Ther Sci. 2017; 29:1305-1310.","DOI":"10.1589\/jpts.29.1305"},{"key":"46885","doi-asserted-by":"crossref","unstructured":"Tenuta M, Tarsitano MG, Mazzotta P, et al. Therapeutic use of pulsed electromagnetic field therapy reduces prostate volume and lower urinary tract symptoms in benign prostatic hyperplasia. Andrology. 2020; 8:1076-1085.","DOI":"10.1111\/andr.12775"},{"key":"46886","doi-asserted-by":"crossref","unstructured":"Giannakopoulos XK, Giotis C, karkabounas S Ch, et al. Effects of pulsed electromagnetic fields on benign prostate hyperplasia. Int Urol Nephrol. 2011; 43:955-60.","DOI":"10.1007\/s11255-011-9944-7"},{"key":"46887","doi-asserted-by":"crossref","unstructured":"Roehrborn CG, Siami P, Barkin J, et al. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the combat study. Eur Urol. 2009; 55:461-471.","DOI":"10.1016\/j.eururo.2008.10.037"}],"container-title":["Archivio Italiano di Urologia e Andrologia"],"original-title":[],"link":[{"URL":"https:\/\/www.pagepressjournals.org\/index.php\/aiua\/article\/download\/aiua.2021.4.501\/9813","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepressjournals.org\/index.php\/aiua\/article\/download\/aiua.2021.4.501\/9813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T07:58:22Z","timestamp":1640159902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pagepressjournals.org\/index.php\/aiua\/article\/view\/aiua.2021.4.501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,22]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,12,20]]}},"URL":"https:\/\/doi.org\/10.4081\/aiua.2021.4.501","relation":{},"ISSN":["2282-4197","1124-3562"],"issn-type":[{"value":"2282-4197","type":"electronic"},{"value":"1124-3562","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,22]]}}}